Fig. 2From: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and TaiwanPatient flow through the extension study. 1Discontinued during overall period: discontinued at any time from start of initial dosing of study drug through the last dose day in the overall periodBack to article page